Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
SCANLUX-370 vs OMNIPAQUE 9
Head-to-head clinical comparison of therapeutic indices and safety profiles.
Radiopaque contrast agent that contains iodine, attenuates X-rays, enhancing vascular and tissue visualization during imaging.
Iodinated nonionic contrast agent that attenuates X-rays, enhancing vascular and tissue contrast. Its iodine content (350 mg/m L) provides radiopacity, while low osmolality reduces adverse hemodynamic effects.
Intravascular administration for computed tomography (CT) and angiography,Opacification of body cavities such as arthrography and hysterosalpingography
Intravascular radiography (angiography, venography, urography),Computed tomography (CT) imaging enhancement,Opacification of the subarachnoid space (myelography),Off-label: CT arthrography, cystography, and fistulography
The typical adult dose of SCANLUX-370 is 0.1 mg/kg administered intravenously as a single dose, up to a maximum of 7 mg.
Omnipaque 9 (iohexol 9 mg I/m L) is administered intravenously. For CT enhancement, typical adult dose is 50-100 m L (450-900 mg I) by slow IV injection.
The terminal elimination half-life of SCANLUX-370 is approximately 1.5-2 hours in patients with normal renal function. This short half-life allows for rapid clearance and minimal accumulation with repeated dosing.
Terminal elimination half-life: 1–2 hours in patients with normal renal function; prolonged to >24 hours in severe renal impairment (Cr Cl <30 m L/min), necessitating dose adjustment.
For patients with GFR 30-60 m L/min: reduce dose by 50%. For GFR <30 m L/min: use is contraindicated.
In patients with GFR 30-59 m L/min: reduce dose by 50% and ensure adequate hydration. With GFR <30 m L/min: avoid use or use only if essential with minimum dose (e.g., 10-20 m L) and nephrology consult.
Risk of acute renal failure, particularly in patients with pre-existing renal impairment, diabetes mellitus, or dehydration.
Iodinated contrast media, including ioxaglate (SCANLUX-370), cross the placenta. First trimester exposure: Theoretical risk of fetal thyroid dysfunction from excess iodine; no documented teratogenicity in human studies. Second and third trimester: Can cause transient neonatal hypothyroidism if administered near term; avoid unless essential. Use only when diagnostic benefit outweighs potential risk.
FDA Category C. No adequate studies in pregnant women. Iodinated contrast crosses placenta. First trimester: theoretical risk of fetal hypothyroidism if administered; third trimester: transient neonatal hypothyroidism reported. Benefits must outweigh risks.
SCANLUX-370 is a contrast agent for CT imaging. Administer via IV bolus at 1-2 m L/s. Monitor for hypersensitivity reactions especially in patients with asthma or allergies. Pre-warming to body temperature reduces viscosity and injection-related discomfort. Ensure adequate hydration pre- and post-procedure to minimize renal injury risk. Do not mix with other drugs in the same syringe.
Omnipaque 9 (iohexol 180 mg/m L) is a nonionic, low-osmolar iodinated contrast agent used primarily for intrathecal administration in myelography due to its low osmolality (408 m Osm/kg) and reduced neurotoxicity. Pre-procedure hydration with normal saline (1-2 m L/kg/h for 4-6 hours) is recommended to minimize contrast-induced nephropathy. Avoid concurrent use of nephrotoxic drugs (e.g., NSAIDs, metformin, aminoglycosides) for 48 hours. Monitor for delayed hypersensitivity reactions (e.g., rash, fever) up to 7 days post-administration. In patients with pheochromocytoma, pretreatment with alpha-blockers is required to prevent hypertensive crisis. Use the smallest volume necessary; maximum total iodine dose should not exceed 3 g iodine (16.7 m L of Omnipaque 9) for intrathecal use.
No interactions on record
No interactions on record
SCANLUX-370 and OMNIPAQUE 9 are distinct pharmacological agents. SCANLUX-370 belongs to the Radiographic Contrast Agent class and is primarily used for Intravascular administration for computed tomography (CT) and angiographyOpacification of body cavities such as arthrography and hysterosalpingography. OMNIPAQUE 9 belongs to the Radiographic Contrast Agent class and is primarily used for Intravascular radiography (angiography, venography, urography)Computed tomography (CT) imaging enhancementOpacification of the subarachnoid space (myelography)Off-label: CT arthrography, cystography, and fistulography. Their specific mechanisms of action, pharmacokinetic characteristics, and side effects differ.
The maternal-fetal safety profiles of these drugs differ. SCANLUX-370 carries a safety status of Category C, whereas OMNIPAQUE 9 safety is classified as Category C. Consult a board-certified physician or healthcare specialist to establish an accurate, individualized pregnancy risk assessment before starting either therapy.
Not metabolized; excreted unchanged via glomerular filtration.
Primarily eliminated unchanged by renal glomerular filtration. No significant hepatic metabolism. Minimal protein binding (<5%).
SCANLUX-370 is primarily eliminated via renal excretion, with approximately 85-90% of the dose recovered unchanged in urine within 24 hours. The remaining 10-15% is excreted unchanged in feces via biliary elimination.
Renal: >95% unchanged via glomerular filtration; fecal: <1%.
SCANLUX-370 exhibits negligible protein binding, with less than 5% bound to plasma proteins, primarily albumin. The low binding ensures rapid distribution and clearance.
Negligible (<1%); does not bind significantly to plasma proteins.
The volume of distribution (Vd) is approximately 0.25-0.3 L/kg, indicating distribution primarily within the extracellular fluid space. This low Vd reflects limited tissue penetration, consistent with its use as an extracellular contrast agent.
0.2–0.3 L/kg; distributes primarily in extracellular fluid, with minimal intracellular penetration.
SCANLUX-370 is administered intravenously and has 100% bioavailability via this route. Oral bioavailability is negligible (less than 1%) due to poor gastrointestinal absorption and extensive first-pass metabolism.
Oral: negligible (<1%) due to poor gastrointestinal absorption; intravenous: 100%.
Child-Pugh Class A: no adjustment. Class B: reduce dose by 25%. Class C: use with caution, maximum dose 0.05 mg/kg.
No specific dose adjustment for Child-Pugh class; however, monitor for contrast-induced nephropathy in ascites (volume status). Use lowest effective dose with hydration.
For children aged 2-12 years: 0.05 mg/kg intravenously, max 3 mg. For infants 6-24 months: 0.03 mg/kg, max 1.5 mg.
Children: 1-2 m L/kg (9-18 mg I/kg) IV; maximum 50 m L total. For neonates: 0.5-1 m L/kg IV slowly.
No specific dose adjustment required, but monitor renal function; consider starting at the lower end of the dosing range due to age-related decline in renal function.
Elderly: use minimum dose (e.g., 25-50 m L) to achieve diagnostic result; pre-hydrate and monitor renal function closely due to age-related GFR decline.
Not to be used for intrathecal administration unless specifically indicated for myelography. Risk of severe adverse reactions including anaphylaxis, cardiac arrest, and seizures. Must have emergency resuscitation equipment available.
No known food interactions. However, patients are typically advised to avoid solid food for 4 hours prior to contrast-enhanced imaging to reduce risk of aspiration if vomiting occurs.
No specific food interactions. However, patients should maintain adequate hydration with water. Avoid alcohol for 24 hours before and after contrast administration due to potential dehydration and increased risk of adverse reactions.
Ioxaglate is excreted into breast milk in minimal amounts; M/P ratio not established. Theoretical risk of direct iodine exposure to infant; consider interrupting breastfeeding for 12-24 hours post-dose with pumping and discarding milk. Infant monitoring for thyroid function not routinely required but caution advised.
Iohexol (active component) is excreted in breast milk in minimal amounts; estimated infant dose <1% of maternal. M/P ratio not established. Discontinue breastfeeding for 24 hours post-administration as precaution.
Pregnancy induces increased plasma volume and renal blood flow, potentially increasing clearance of ioxaglate. However, standard weight-based dosing may be insufficient; consider dose adjustment based on estimated glomerular filtration rate (e GFR) to maintain diagnostic image quality while minimizing fetal exposure. No established pregnancy-specific dosing guidelines; clinical judgment required.
Pregnancy does not significantly alter iohexol pharmacokinetics; no dose adjustment required. Use lowest effective dose to minimize fetal exposure.
Inform your doctor if you have allergies, asthma, kidney problems, or are taking metformin.,Drink plenty of water before and after the procedure to help protect your kidneys.,You may experience a warm sensation or metallic taste during injection; this is temporary.,Report any difficulty breathing, hives, itching, or swelling immediately after contrast administration.,Breastfeeding should be avoided for 24 hours after receiving this contrast agent.
Drink plenty of water before and after the procedure unless instructed otherwise.,Inform your doctor if you have a history of allergic reactions to contrast agents, asthma, or allergies.,Tell your doctor if you are pregnant, breastfeeding, or planning to become pregnant.,If you take metformin, you may need to stop it 48 hours before and after the procedure.,Rarely, contrast may cause kidney problems; report any changes in urination or swelling.,You may experience transient headache, nausea, or warmth after injection; these are usually mild.,Do not operate machinery or drive for 24 hours after the procedure if sedation is used.